Last reviewed · How we verify
ARV-471 in combination with Everolimus — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ARV-471 in combination with Everolimus (arv-471-in-combination-with-everolimus) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ARV-471 in combination with Everolimus TARGET | arv-471-in-combination-with-everolimus | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ARV-471 in combination with Everolimus CI watch — RSS
- ARV-471 in combination with Everolimus CI watch — Atom
- ARV-471 in combination with Everolimus CI watch — JSON
- ARV-471 in combination with Everolimus alone — RSS
Cite this brief
Drug Landscape (2026). ARV-471 in combination with Everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/arv-471-in-combination-with-everolimus. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab